Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1806-1813

  Carlson, Bradley A ^a   Yoo, Min Hyuk ^a   Tobe, Ryuta ^a   Mueller, Charles ^a   Naranjo Suarez, Salvador ^a   Hoffmann, Victoria J ^b   Gladyshev, Vadim N ^c   Hatfield, Dolph L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; DIETHYLNITROSAMINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE 2; THIOREDOXIN REDUCTASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INCIDENCE; CONTROLLED STUDY; ENZYME METABOLISM; FEMALE; HOMEOSTASIS; LIVER CARCINOGENESIS; LIVER TUMOR; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; BODY WEIGHT; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HOMEOSTASIS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; OXIDATION-REDUCTION; THIOREDOXIN REDUCTASE 1;

EID: 84865545696     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs230     Document Type: Article

References (43)

1. Gromer, S. et al. (2005) Human selenoproteins at a glance. Cell. Mol. Life Sci., 62, 2414-2437.
2. Holmgren, A. (2006) Selenoproteins of the thioredoxin system. In Hatfield, D.L., Berry, M.J., Gladyshev, V.N., (eds). Selenium: Its Molecular Biology and Role In Human Health. 2nd edition. Springer Science+Business Media, New York, NY, pp. 183-194.
3. Arnér, E.S. et al. (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem., 267, 6102-6109.
4. Turanov, A.A. et al. (2010) Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem. J., 430, 285-293.
5. Jakupoglu, C. et al. (2005) Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol. Cell. Biol., 25, 1980-1988.
6. Bondareva, A.A. et al. (2007) Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome. Free Radic. Biol. Med., 43, 911-923.
7. Rundlöf, A.K. et al. (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal., 6, 41-52.
8. Biaglow, J.E. et al. (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther., 4, 6-13.
9. Arnér, E.S. et al. (2006) The thioredoxin system in cancer. Semin. Cancer Biol., 16, 420-426.
10. Fujino, G. et al. (2006) Thioredoxin and protein kinases in redox signaling. Semin. Cancer Biol., 16, 427-435.
11. Mandal, P.K. et al. (2010) Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res., 70, 9505-9514.
12. Montero, A.J. et al. (2011) Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs, 71, 1385-1396.
13. Selenius, M. et al. (2010) Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid. Redox Signal., 12, 867-880.
14. Merrill, G.F. et al. (1999) The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase. Cancer Res., 59, 3175-3179.
15. Moos, P.J. et al. (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J. Biol. Chem., 278, 745-750.
16. Urig, S. et al. (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol., 16, 452-465.
17. Hatfield, D.L. et al. (2009) Selenoproteins that function in cancer prevention and promotion. Biochim. Biophys. Acta, 1790, 1541-1545.
18. Yoo, M.-H. et al. (2012) Selenoproteins harboring a split personality in both preventing and promoting cancer. In Hatfield, D.L., Berry, M.J., Gladyshev, V.N., (eds). Selenium: Its Molecular Biology and Role In Human Health. 3rd edition. Springer Science+Business Media, New York, NY, pp. 325-333.
19. Scarbrough, P.M. et al. (2012) Simultaneous inhibition of glutathioneand thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic. Biol. Med., 52, 436-443.
20. Simons, A.L. et al. (2009) Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells. J. Oncol., 2009, 519563.
21. Prigge, J.R. et al. (2012) Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1. Free Radic. Biol. Med., 52, 803-810.
22. Fath, M.A. et al. (2011) Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin. Cancer Res., 17, 6206-6217.
23. Yoo, M.H. et al. (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem., 281, 13005-13008.
24. Carlson, B.A. et al. (2004) Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J. Biol. Chem., 279, 8011-8017.
25. Mohr, U. (2001) International Classification of Rodent Tumors. The Mouse. Springer-Verlag, New York, NY.
26. Rollins, M.F. et al. (2010) Hepatocytes lacking thioredoxin reductase 1 have normal replicative potential during development and regeneration. J. Cell. Sci., 123(Pt 14), 2402-2412.
27. Brigelius-Flohé, R. et al. (2009) Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta, 1790, 1555-1568.
28. Banning, A. et al. (2012) Glutathione Peroxidase 2 and Its Role in Cancer. In Hatfield, D.L., Berry, M.J., Gladyshev, V.N., (eds). Selenium: Its molecular biology and role in human health. 3rd edition. Springer Science+Business Media, New York, NY, pp. 271-282.
29. Estrela, J.M. et al. (2006) Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci., 43, 143-181.
30. Franco, R. et al. (2009) Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ., 16, 1303-1314.
31. Corti, A. et al. (2010) Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res., 30, 1169-1181.
32. Montero, A.J. et al. (2011) Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs, 71, 1385-1396.
33. Bondareva, A.A. et al. (2007) Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome. Free Radic. Biol. Med., 43, 911-923.
34. Suvorova, E.S. et al. (2009) Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS ONE, 4, e6158.
35. Kensler, T.W. et al. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol., 47, 89-116.
36. Okawa, H. et al. (2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun., 339, 79-88.
37. Slocum, S.L. et al. (2011) Nrf2: control of sensitivity to carcinogens. Arch. Toxicol., 85, 273-284.
38. Gladyshev, V.N. et al. (1998) Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem. Biophys. Res. Commun., 251, 488-493.
39. Copeland, P.R. et al. (2000) A novel RNA binding protein, SBP2, is required for the translation of mammalian selenoprotein mRNAs. EMBO J., 19, 306-314.
40. Low, S.C. et al. (2000) SECIS-SBP2 interactions dictate selenocysteine incorporation efficiency and selenoprotein hierarchy. EMBO J., 19, 6882-6890.
41. Kang, J.S. et al. (2007) Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res., 67, 11141-11146.
42. Felix, K. et al. (2004) Selenium deficiency abrogates inflammation-dependent plasma cell tumors in mice. Cancer Res., 64, 2910-2917.
43. Novoselov, S.V. et al. (2005) Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene, 24, 8003-8011.